Janssen, one of the Janssen pharmaceutical companies of Johnson & Johnson, announced today the launch of INVOKANA® (canagliflozin), a highly differentiated and important new treatment option for the estimated 67 million people2 suffering from diabetes in India, which has the world’s second largest diabetes population.
Taken orally once a day, INVOKANA® belongs to a new class of medications called sodium glucose (sugar) co-transporter 2 (SGLT2) inhibitors which work in a completely different way to other classes of type 2 diabetes medications. INVOKANA® has been shown to reduce glucose levels in adults who have previously not been able to achieve adequate control through diet and lifestyle measures, or through treatment with other blood sugar-lowering medicines.1
Type 2 diabetes is a serious chronic disease that causes glucose levels in the blood to become too high. In 2014, an estimated 4.9 million worldwide deaths were directly caused by diabetes2 and associated conditions such as cardiovascular disease.
“The launch of INVOKANA® in India is an exciting milestone for Janssen,” commented Sanjiv Navangul, Managing Director, Janssen India. “With the relentless increase in the number of people with type 2 diabetes in the country, there is an ongoing need for additional treatment options.”
Taken orally once a day, INVOKANA® belongs to a new class of medications called sodium glucose (sugar) co-transporter 2 (SGLT2) inhibitors which work in a completely different way to other classes of type 2 diabetes medications. INVOKANA® has been shown to reduce glucose levels in adults who have previously not been able to achieve adequate control through diet and lifestyle measures, or through treatment with other blood sugar-lowering medicines.1
Type 2 diabetes is a serious chronic disease that causes glucose levels in the blood to become too high. In 2014, an estimated 4.9 million worldwide deaths were directly caused by diabetes2 and associated conditions such as cardiovascular disease.
“The launch of INVOKANA® in India is an exciting milestone for Janssen,” commented Sanjiv Navangul, Managing Director, Janssen India. “With the relentless increase in the number of people with type 2 diabetes in the country, there is an ongoing need for additional treatment options.”
